Teva Pharmaceutical Industries Limited 2021 Q3 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha
Dimite el CEO del laboratorio Teva en medio de una crisis de confianza | Reuters
Teva Reports Third Quarter 2020 Financial Results | Business Wire
Teva Reports Second Quarter 2022 Financial Results | Business Wire
Teva presents interim results from PEARL study on migraine treatment - European Pharmaceutical Manufacturer
Teva raises 2018 guidance after Q2 results - Globes
Teva: ventas caen -5,6% en semestre | PharmaBiz.NET
Teva Pharmaceuticals on Twitter: "Teva just announced its Q2 2022 financial results. View the press release here: https://t.co/OGECc00hWU Forward-looking statements are subject to the cautionary note included in our Q2 2022 press
Teva's new CEO Schultz to take post Wednesday | The Times of Israel
Teva presents positive migraine drug results
Five Considerations After Teva Pharmaceuticals' Q3 Report (NYSE:TEVA) | Seeking Alpha
Teva Pharma shares up after positive results from migraine drug trial: Tirrell
Teva Reports First Quarter 2022 Financial Results | Business Wire
Can Teva Pharmaceutical's Q4 results bring positive surprise? | Seeking Alpha
Analysts see upside in Teva share price - גלובס
Teva: ventas caen -5,6% en semestre | PharmaBiz.NET
Migraine treatment results in Japan boost Teva - Globes
Teva to cut up to 1,700 jobs in streamlining plan — report | The Times of Israel
Teva Pharmaceutical Industries Limited 2020 Q4 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha
Teva Reports Fourth Quarter and Full Year 2019 Financial Results | Business Wire
Infographic: Teva Pharmaceuticals (TEVA) Q1 2020 earnings results | AlphaStreet
Teva Reports Fourth Quarter and Full Year 2020 Financial Results | Business Wire
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
2021 Season Results: TEVA Corporation
Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement - FactEntry
Teva Reports Third Quarter 2021 Financial Results | Business Wire
Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease - Huntington's Disease News
